Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| B1871016 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study comparing 2 formulations of bosutinib in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Commercial Tablet |
|
| 2 | Experimental | Clinical Tablet |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SKI-606 (Bosutinib) | Drug | 500 mg commercial formulation film coated tablet, administered once daily |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics, as measured by Cmax, AUC, tmax, t1/2 | 2 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Tacoma | Washington | 98418 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C471992 | bosutinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| SKI-606 (Bosutinib) | Drug | 500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily |
|
|